Group 1 - The core issue is that Guangdong Tuosda Technology Co., Ltd. has received a warning letter from the Guangdong Securities Regulatory Bureau due to multiple financial discrepancies, including inaccurate revenue and cost accounting, improper provision for bad debts, and non-compliance in the use of raised funds [1] - The warning letter indicates that the company, along with its executives, will face regulatory measures due to these violations, which could lead to civil liability for damages to investors [1] - Investors affected by the company's actions are encouraged to register for compensation claims, particularly those who purchased securities between April 22, 2024, and December 30, 2025, and sold or held them after December 31, 2025 [2] Group 2 - The potential civil lawsuits against the company will not be affected by whether the company is delisted, but entering bankruptcy proceedings could significantly impact the litigation process [3] - Investors seeking to register for compensation must provide specific documentation, including a copy of their ID, securities account information, and transaction records [3]

Core Viewpoint - The article discusses the ongoing legal actions against Hainan Huatie (603300) for false statements and incomplete disclosures related to a significant contract, which has led to investor claims for compensation. Group 1: Legal Proceedings - Hainan Huatie's investors are filing claims for compensation due to alleged false statements and incomplete disclosures regarding a major contract [1][3] - The law firm Shanghai Jiucheng, represented by lawyer Xu Feng, has submitted multiple claims to the Hangzhou Intermediate People's Court and is awaiting further court arrangements [1][3] Group 2: Contractual Issues - The company signed a "Computing Power Service Agreement" on March 3, 2025, with a total contract value of 3.69 billion yuan, but failed to disclose critical terms that significantly impact the contract's execution [2][4] - The agreement allowed the counterparty to unilaterally terminate orders without liability, which was not disclosed in the company's announcement on March 5, 2025 [2][4] Group 3: Disclosure Failures - Hainan Huatie's subsidiary, Huatie Dahuangfeng, did not meet the delivery deadline set for the end of April 2025 and failed to timely disclose the subsequent changes to the delivery schedule [2][4] - The company signed two amendments to the delivery schedule on June 27 and August 29, 2025, but did not disclose these changes as required [2][4]

Core Viewpoint - Panda Financial Holdings Co., Ltd. (ST Panda, stock code: 600599) is under investigation by the China Securities Regulatory Commission (CSRC) for suspected violations of information disclosure laws, leading to a formal case being opened against the company [1][5]. Financial Performance - On April 28, 2025, Panda Financial corrected its 2024 annual performance forecast, initially predicting a net profit of 30 million to 45 million yuan. The revised forecast now indicates a projected net loss of 460 million to 480 million yuan for the same period [2][6]. - The adjusted forecast for net profit after deducting non-recurring gains and losses is now estimated to be a loss of 470 million to 490 million yuan [2][6]. Legal Proceedings - In response to the CSRC's investigation, a lawyer from Shanghai Hanlian Law Firm is collecting claims from investors who purchased Panda Financial's securities between December 2, 2024, and April 27, 2025, and either sold or continued to hold them after April 28, 2025 [3][7]. - Investors seeking compensation must provide specific documentation, including a copy of their ID, a confirmation of their securities account, and transaction records [4][8]. Investor Rights - Under Chinese law, companies and their executives may be held liable for damages resulting from false statements that harm investors, covering losses such as investment differences, commissions, stamp duties, and interest losses [2][6]. - The process for civil claims is not affected by whether the company is delisted, but entering bankruptcy proceedings could significantly impact the litigation process [4][8].

Core Viewpoint - The news highlights ongoing legal actions against Zhenlei Technology and Century Huatong for alleged false statements and violations of information disclosure regulations, leading to investor compensation claims. Group 1: Zhenlei Technology - Zhenlei Technology has been implicated in a false statement case, prompting the initiation of investor compensation claims [1][4] - On December 26, 2025, Zhenlei Technology announced it received a notice from the China Securities Regulatory Commission (CSRC) regarding an investigation into information disclosure violations [1][4] - Investors who purchased Zhenlei Technology shares on December 27, 2025, or later may prepare to file for compensation [1][4] Group 2: Century Huatong - Century Huatong received an administrative penalty decision from the CSRC on November 6, 2024, detailing multiple violations from 2018 to 2022 [2][5] - The company failed to conduct goodwill impairment tests as required, resulting in an underreporting of goodwill impairment provisions by 62.363 million yuan in 2018 [5][6] - Century Huatong is also accused of fabricating software copyright transfer transactions, leading to inflated revenue figures for 2020 and 2021 [6][7] - Investors who bought Century Huatong shares between April 27, 2019, and July 25, 2023, and sold or held them afterward are eligible to file for compensation [6][7]

Core Viewpoint - Hunan Kexin Information Technology Co., Ltd. (Kexin Information) is facing administrative penalties from the China Securities Regulatory Commission (CSRC) for accounting irregularities that led to inflated financial statements [2][6]. Group 1: Allegations and Financial Impact - In April 2023, Kexin Information engaged in server and application software sales with Dayou Digital Technology, despite lacking control over the goods, and improperly recognized revenue using the total amount method, violating accounting standards [2][6]. - The company's actions resulted in a reported inflated revenue of 46,320,193.97 yuan, which accounted for 33.57% of the disclosed revenue for the period [2][6]. - Additionally, inflated costs amounted to 32,601,645.30 yuan, also representing 33.57% of the disclosed costs, and inflated profits reached 12,792,144.79 yuan, making up 71.94% of the total reported profit [2][6]. Group 2: Legal and Compensation Actions - Following the allegations, Kexin Information issued a correction announcement on April 27, 2024, to amend its previous financial data [2][6]. - Affected investors are encouraged to register for compensation claims through legal representation, with specific conditions for eligibility based on their trading activities between August 19, 2023, and April 26, 2024 [3][7]. - The compensation claims will cover investment differences, commissions, and stamp duties, and investors must provide necessary documentation for their claims [4][8].

Core Viewpoint - The article discusses ongoing legal actions for investor compensation against Nanjing Panda Electronics due to significant discrepancies between the company's profit forecasts and actual financial results, indicating potential false statements made by the company [1][2]. Group 1: Company Financial Discrepancies - Nanjing Panda announced an estimated net profit for 2023 of approximately 16.19 million to 24.29 million yuan, with a net profit excluding non-recurring gains and losses expected to be between -3.27 million and 4.82 million yuan [1]. - The actual net profit reported on March 29, 2024, was a loss of 237.86 million yuan, and the net profit excluding non-recurring gains and losses was a loss of 257.01 million yuan, showing a significant deviation from the earlier forecast [1]. Group 2: Legal Actions and Investor Rights - Investors who purchased Nanjing Panda stock between January 31, 2024, and March 29, 2024, and sold or continued to hold the stock after March 29, 2024, are eligible to initiate compensation claims [2]. - The law firm involved has a history of successfully representing investors in similar cases, having handled nearly 200 cases with favorable outcomes and currently managing around 300 ongoing claims [2].

Core Viewpoint - The article discusses the ongoing legal actions against Guangyuyuan (stock code: 600771) for false statements made between 2016 and 2021, leading to investor claims for compensation due to misleading financial disclosures [1][2]. Group 1: Legal Proceedings - The law firm Shanghai Jiucheng, represented by lawyer Xu Feng, has submitted multiple claims to the Taiyuan Intermediate People's Court regarding investor compensation for Guangyuyuan [1]. - The law firm continues to accept claims from other investors who have suffered losses due to the company's misleading financial practices [1]. Group 2: Regulatory Findings - On April 11, 2024, Guangyuyuan received an administrative penalty decision from the Shanxi Regulatory Bureau of the China Securities Regulatory Commission, confirming violations related to the company's financial reporting [1]. - The company was found to have misrepresented its "buyout sales" model in annual reports from 2016 to 2021, including improper revenue recognition and incorrect handling of sales expenses [1]. Group 3: Investor Compensation Eligibility - Investors who purchased Guangyuyuan stock between March 21, 2017, and December 29, 2023, and sold or continued to hold the stock after December 29, 2023, are eligible to initiate compensation claims [2]. - The law firm has a history of successfully representing investors in similar cases, with nearly 200 stocks resulting in victories or settlements [2].

Core Viewpoint - The news discusses ongoing legal actions regarding investor claims against Jihua Group and Century Huatong due to alleged violations of information disclosure laws and false financial reporting [1][3][5]. Group 1: Jihua Group - On December 18, 2025, a lawyer representing Jihua Group investors submitted another claim to the court, following multiple previous submissions, and is awaiting further court arrangements [1]. - Jihua Group received a notice from the China Securities Regulatory Commission (CSRC) on August 8, 2025, indicating that the company is under investigation for suspected violations of information disclosure laws [1][4]. - Investors who purchased Jihua Group stock before August 9, 2025, and sold or continued to hold it after that date are eligible to initiate claims [2][4]. Group 2: Century Huatong - On November 6, 2024, Century Huatong announced it received an administrative penalty decision from the CSRC, revealing false records in its annual reports from 2018 to 2022 regarding goodwill and fictitious software copyright transfer transactions [3][5]. - Investors who bought Century Huatong stock between April 27, 2019, and July 25, 2023, and sold or continued to hold it after July 25, 2023, can also initiate claims [3][5]. - Some previous claims by Century Huatong investors have already resulted in compensation [2][4].

2025年12月22日，上海久诚律师事务所股民索赔律师许峰代理的长药控股（300391）虚假陈述投资者索 赔案再向武汉市中级人民法院提交一次立案。需要特别提示的是，长药控股投资者索赔案已有投资者胜 诉先例。 长江医药控股股份有限公司自查中发现，罗明及其实际控制的湖北长江大药房连锁有限公司因资金占用 导致公司下属子公司、长江星及其下属子公司与相关往来单位账实不符。截至报告期末，公司存在资金 占用179，662，019.54元，占公司最近一期经审计归母净资产的92.08%。公司将通过关联方债权债务转 让方式全部清偿关联方占用的资金。 责任编辑：韦子蓉 专门从事股票索赔法律事务的上海久诚律师事务所主任许峰律师认为，根据前期投资者胜诉判决，在 2019年3月30日到2024年4月30日之间买入长药控股股票，并且在2024年4月30日后卖出或继续持有股票 的投资者，目前还可发起索赔。（长药控股维权入口） （本文由上海久诚律师事务所主任许峰律师供稿，不代表新浪财经立场。许峰律师，2008年起律师执 业，执业服务范围涉及虚假陈述、内幕交易、操纵市场等证券欺诈领域索赔代理。十几年来已代理近两 百只股票的投资者胜诉或调解获赔， ...

Core Viewpoint - Jiangsu Nuotai Aosaino Biopharmaceutical Co., Ltd. (Nuotai Biopharma) has been found guilty of falsifying financial statements and providing misleading information in its public offerings, leading to administrative penalties from the China Securities Regulatory Commission (CSRC) [1][3][9]. Group 1: Financial Misconduct - Nuotai Biopharma's 2021 annual report contained false records, including a reported revenue of 30 million yuan from a technology transfer to Zhejiang Huabei Pharmaceutical, which lacked the financial capability to pay for the transaction [1][7]. - The technology transfer was deemed to lack commercial substance, resulting in an inflated revenue of 30 million yuan and an inflated profit of 25.9516 million yuan, accounting for 20.64% of the total profit reported for that period [1][7]. Group 2: Public Offering Irregularities - Nuotai Biopharma fabricated significant false content in its public offering documents, particularly in the financial accounting information section of its bond issuance prospectus [2][8]. - The company issued convertible bonds totaling 434 million yuan, with the issuance process and financial data being compromised due to the previously mentioned inflated figures [2][8]. Group 3: Regulatory Actions and Legal Implications - The CSRC has mandated corrections, issued warnings, and imposed fines on Nuotai Biopharma and its actual controller Zhao Dezhong, along with other responsible personnel [3][9]. - Affected investors are encouraged to register for compensation claims, as they may pursue civil litigation for damages resulting from the company's misleading statements [3][10].